Prognostic markers in small cell lung cancer

Myles Nickolich, Afshin Dowlati

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Small cell lung cancer (SCLC) is a rapidly progressive malignancy with no improvement in survival outcome or change in the standard of care over the past thirty years. In this review, we examine molecular tissue markers, serum/plasma markers, laboratory data and clinical markers that have been reported to have prognostic influence in SCLC. We discovered that the following held a poor prognosis in limited (LD) and extensive-stage (ED) SCLC: Autocrine growth loop activity via C-kit, gastrin-releasing peptide, or pro-gastrin releasing peptide, high pre-treatment beta fibro-blast growth factor, increased cathepsin B or D expression, reduced intracellular fragile histidine triad protein expression, her-2/neu over-expression, high matrix metalloproteinase-11 or -14 activity, loss of function of Rb, elevated serum levels of ALT, CEA, CRP, LDH, or VEGF, hyponatremia, elevated lymphatic/vascular endothelial progenitor, disease extent, male gender, weight loss, anemia, neutrophilia, thrombocytopenia, prolonged PT or aPTT, and superior vena cava syndrome as part of an initial presentation of disease. Hypourecemia, elevated neuron-specific enolase, and age over 70 years conveyed a poorer prognosis in LD and elevated creatinine, higher performance status (>2), and liver, bone, or brain me-tastases conveyed a poorer prognosis in ED SCLC. The following conveyed a favorable prognosis in LD and ED SCLC: E-cadherin expression, increased cytoplasmic levels of inhibitor of DNA binding/differentiation-2, increased numbers of tumor-infiltrating lymphocytes, high MAPK activity, normal to elevated albumin levels, female gender, performance status <2, and smoking cessation at time of diagnosis. Age <70 and the absence of a pleural effusion were associated with a better prognosis in LD only. The data supporting many of these prognostic factors are somewhat weak and reflect that lack of translational research in this disease.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalCurrent Cancer Therapy Reviews
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Small Cell Lung Carcinoma
Gastrin-Releasing Peptide
Biomarkers
Matrix Metalloproteinase 11
Superior Vena Cava Syndrome
Tumor-Infiltrating Lymphocytes
Cathepsin B
Cathepsin D
Translational Medical Research
Phosphopyruvate Hydratase
Hyponatremia
Smoking Cessation
Pleural Effusion
Cadherins
Standard of Care
Thrombocytopenia
Vascular Endothelial Growth Factor A
Blood Vessels
Anemia
Weight Loss

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Nickolich, Myles ; Dowlati, Afshin. / Prognostic markers in small cell lung cancer. In: Current Cancer Therapy Reviews. 2014 ; Vol. 10, No. 1. pp. 39-46.
@article{26491784867640048e121345572725ab,
title = "Prognostic markers in small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) is a rapidly progressive malignancy with no improvement in survival outcome or change in the standard of care over the past thirty years. In this review, we examine molecular tissue markers, serum/plasma markers, laboratory data and clinical markers that have been reported to have prognostic influence in SCLC. We discovered that the following held a poor prognosis in limited (LD) and extensive-stage (ED) SCLC: Autocrine growth loop activity via C-kit, gastrin-releasing peptide, or pro-gastrin releasing peptide, high pre-treatment beta fibro-blast growth factor, increased cathepsin B or D expression, reduced intracellular fragile histidine triad protein expression, her-2/neu over-expression, high matrix metalloproteinase-11 or -14 activity, loss of function of Rb, elevated serum levels of ALT, CEA, CRP, LDH, or VEGF, hyponatremia, elevated lymphatic/vascular endothelial progenitor, disease extent, male gender, weight loss, anemia, neutrophilia, thrombocytopenia, prolonged PT or aPTT, and superior vena cava syndrome as part of an initial presentation of disease. Hypourecemia, elevated neuron-specific enolase, and age over 70 years conveyed a poorer prognosis in LD and elevated creatinine, higher performance status (>2), and liver, bone, or brain me-tastases conveyed a poorer prognosis in ED SCLC. The following conveyed a favorable prognosis in LD and ED SCLC: E-cadherin expression, increased cytoplasmic levels of inhibitor of DNA binding/differentiation-2, increased numbers of tumor-infiltrating lymphocytes, high MAPK activity, normal to elevated albumin levels, female gender, performance status <2, and smoking cessation at time of diagnosis. Age <70 and the absence of a pleural effusion were associated with a better prognosis in LD only. The data supporting many of these prognostic factors are somewhat weak and reflect that lack of translational research in this disease.",
author = "Myles Nickolich and Afshin Dowlati",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/157339471001140815152154",
language = "English (US)",
volume = "10",
pages = "39--46",
journal = "Current Cancer Therapy Reviews",
issn = "1573-3947",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

Prognostic markers in small cell lung cancer. / Nickolich, Myles; Dowlati, Afshin.

In: Current Cancer Therapy Reviews, Vol. 10, No. 1, 01.01.2014, p. 39-46.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Prognostic markers in small cell lung cancer

AU - Nickolich, Myles

AU - Dowlati, Afshin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Small cell lung cancer (SCLC) is a rapidly progressive malignancy with no improvement in survival outcome or change in the standard of care over the past thirty years. In this review, we examine molecular tissue markers, serum/plasma markers, laboratory data and clinical markers that have been reported to have prognostic influence in SCLC. We discovered that the following held a poor prognosis in limited (LD) and extensive-stage (ED) SCLC: Autocrine growth loop activity via C-kit, gastrin-releasing peptide, or pro-gastrin releasing peptide, high pre-treatment beta fibro-blast growth factor, increased cathepsin B or D expression, reduced intracellular fragile histidine triad protein expression, her-2/neu over-expression, high matrix metalloproteinase-11 or -14 activity, loss of function of Rb, elevated serum levels of ALT, CEA, CRP, LDH, or VEGF, hyponatremia, elevated lymphatic/vascular endothelial progenitor, disease extent, male gender, weight loss, anemia, neutrophilia, thrombocytopenia, prolonged PT or aPTT, and superior vena cava syndrome as part of an initial presentation of disease. Hypourecemia, elevated neuron-specific enolase, and age over 70 years conveyed a poorer prognosis in LD and elevated creatinine, higher performance status (>2), and liver, bone, or brain me-tastases conveyed a poorer prognosis in ED SCLC. The following conveyed a favorable prognosis in LD and ED SCLC: E-cadherin expression, increased cytoplasmic levels of inhibitor of DNA binding/differentiation-2, increased numbers of tumor-infiltrating lymphocytes, high MAPK activity, normal to elevated albumin levels, female gender, performance status <2, and smoking cessation at time of diagnosis. Age <70 and the absence of a pleural effusion were associated with a better prognosis in LD only. The data supporting many of these prognostic factors are somewhat weak and reflect that lack of translational research in this disease.

AB - Small cell lung cancer (SCLC) is a rapidly progressive malignancy with no improvement in survival outcome or change in the standard of care over the past thirty years. In this review, we examine molecular tissue markers, serum/plasma markers, laboratory data and clinical markers that have been reported to have prognostic influence in SCLC. We discovered that the following held a poor prognosis in limited (LD) and extensive-stage (ED) SCLC: Autocrine growth loop activity via C-kit, gastrin-releasing peptide, or pro-gastrin releasing peptide, high pre-treatment beta fibro-blast growth factor, increased cathepsin B or D expression, reduced intracellular fragile histidine triad protein expression, her-2/neu over-expression, high matrix metalloproteinase-11 or -14 activity, loss of function of Rb, elevated serum levels of ALT, CEA, CRP, LDH, or VEGF, hyponatremia, elevated lymphatic/vascular endothelial progenitor, disease extent, male gender, weight loss, anemia, neutrophilia, thrombocytopenia, prolonged PT or aPTT, and superior vena cava syndrome as part of an initial presentation of disease. Hypourecemia, elevated neuron-specific enolase, and age over 70 years conveyed a poorer prognosis in LD and elevated creatinine, higher performance status (>2), and liver, bone, or brain me-tastases conveyed a poorer prognosis in ED SCLC. The following conveyed a favorable prognosis in LD and ED SCLC: E-cadherin expression, increased cytoplasmic levels of inhibitor of DNA binding/differentiation-2, increased numbers of tumor-infiltrating lymphocytes, high MAPK activity, normal to elevated albumin levels, female gender, performance status <2, and smoking cessation at time of diagnosis. Age <70 and the absence of a pleural effusion were associated with a better prognosis in LD only. The data supporting many of these prognostic factors are somewhat weak and reflect that lack of translational research in this disease.

UR - http://www.scopus.com/inward/record.url?scp=84906896573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906896573&partnerID=8YFLogxK

U2 - 10.2174/157339471001140815152154

DO - 10.2174/157339471001140815152154

M3 - Review article

AN - SCOPUS:84906896573

VL - 10

SP - 39

EP - 46

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

SN - 1573-3947

IS - 1

ER -